Home › Studies › PRJEB73985
PRJEB73985 ERP158686

Oat vs spelt bran fiber in MASLD: RCT, Germany/Austria

Oat beta glucan versus iso dietary fiber or placebo in MASLD: A multicenter, randomized, placebo-controlled dietary study

175 gut metagenome samples from adults with steatotic liver disease (MASLD) in Germany and Austria, from a randomized, double-blind, placebo-controlled dietary trial comparing oat bran, spelt bran, and placebo fiber supplementation. machine-written summary

175 samples · 175 runs · DE, AT · Adult · 2025 · 11.67 Gbp / sample

Sources
✓Sequence archive 700✓Abstract / description 350✓Full text 175○Supplementary tables–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive700 sample values (collection date, country, subject id, timepoint)
✓ Abstract / description350 sample values (health condition, health condition detail)
✓ Full text175 sample values (antibiotic exposure) · PMC12721201
○ Supplementary tablesfiles read; no table could be matched to the samples
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet
– Human verifiednot yet checked by a person · I checked this project — verify it
Interventions

intervention — arms not resolved

Prebiotic / dietary fibre supplement design randomized_controlled_trial · population liver_disease · Oat bran β-glucan vs spelt bran fiber vs low-fiber placebo, 12 weeks

“Oat beta glucan versus iso dietary fiber or placebo in MASLD” — study.title (study level; per-sample arms are in the intervention column below)

Samples at a glance
2 countries
Age
adult175
Condition
liver_disease175
Country
DE90
AT85
Body site
primary175
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)all projects, 0.03–0.1 Gbp: 17,066 samples (3 %)all projects, 0.1–0.3 Gbp: 29,179 samples (5 %)all projects, 0.3–1 Gbp: 47,044 samples (8 %)all projects, 1–3 Gbp: 124,983 samples (22 %)all projects, 3–10 Gbp: 253,728 samples (44 %)this project, 3–10 Gbp: 86 samplesall projects, 10–30 Gbp: 72,533 samples (13 %)this project, 10–30 Gbp: 88 samplesall projects, 30–100 Gbp: 3,024 samples (1 %)this project, 30–100 Gbp: 1 samplesall projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 11.67 Gbp per sample0130Gbp
Sampling design and relatedness

longitudinal

38 of 38 people sampled more than once (175 samples; median 5, up to 5 per person) · follow-up median 5 mo (max 5 mo) · median interval between samples 21 d (time from timepoint labels). Schedule stated by the source: “Samples collected at Week -3W (run-in), 0W, 2W, 12W, and 20W (follow-up) relative to intervention start.” (time origin: intervention start); stated follow-up 56 d.

A001A001: day 0A001: day 14A001: day 84A001: day 140A002A002: day 0A002: day 14A002: day 21A002: day 84A002: day 140A004A004: day 0A004: day 14A004: day 21A004: day 84A004: day 140A006A006: day 0A006: day 14A006: day 21A006: day 84A006: day 140A007A007: day 0A007: day 14A007: day 21A007: day 84A007: day 140A009A009: day 0A009: day 14A009: day 84A009: day 140A010A010: day 0A010: day 14A010: day 21A010: day 84A010: day 140A013A013: day 0A013: day 14A013: day 21A013: day 84A013: day 140A014A014: day 0A014: day 14A014: day 21A014: day 140A015A015: day 0A015: day 14A015: day 21A015: day 84A015: day 140A016A016: day 0A016: day 14A016: day 21A016: day 84A016: day 140A018A018: day 0A018: day 14A018: day 21A018: day 84A018: day 140A019A019: day 0A019: day 14A019: day 21A019: day 84A019: day 140A020A020: day 0A020: day 14A020: day 21A020: day 84A020: day 140A021A021: day 0A021: day 14A021: day 21A021: day 84A021: day 140A022A022: day 0A022: day 14A022: day 21A022: day 84A022: day 140A027A027: day 0A027: day 14A027: day 21A027: day 84A027: day 140A028A028: day 0A028: day 14A028: day 84A028: day 140A031A031: day 0A031: day 21A031: day 84A031: day 140V001V001: day 0V001: day 14V001: day 21V002V002: day 0V002: day 14V002: day 84V002: day 140V003V003: day 0V003: day 14V003: day 21V003: day 84V003: day 140V004V004: day 0V004: day 14V004: day 21V004: day 84V004: day 140V005V005: day 0V005: day 14V005: day 21V005: day 84V005: day 140V006V006: day 0V006: day 14V006: day 21V006: day 84V006: day 140V007V007: day 0V007: day 14V007: day 21V007: day 84V007: day 140V008V008: day 0V008: day 14V008: day 21V009V009: day 0V009: day 14V009: day 21V009: day 84V009: day 140V010V010: day 0V010: day 14V010: day 21V010: day 84V010: day 140V011V011: day 0V011: day 14V011: day 21V011: day 84V011: day 140V013V013: day 0V013: day 14V013: day 21V013: day 84V013: day 140V014V014: day 0V014: day 14V014: day 21V014: day 84V014: day 140V015V015: day 0V015: day 14V015: day 21V015: day 84V015: day 140V016V016: day 0V016: day 14V016: day 21V016: day 84V016: day 140V018V018: day 0V018: day 14V018: day 21V018: day 84V018: day 140V019V019: day 0V019: day 14V019: day 21V019: day 84V019: day 1400 d35 d2 mo3 mo5 mo

Each row is one person (36 shown of 38); dots are samples at days since that person's first sample.

How longitudinal and relatedness information is derived

Community composition
Roseburia 8.4%Phocaeicola 7.3%Bacteroides 7.2%Blautia_A 7.0%Faecalibacterium 5.5%Ruminococcoides 4.6%Bifidobacterium 4.4%Prevotella 3.9%Gemmiger 2.4%Anaerostipes 2.1%Alistipes 1.9%Collinsella 1.9%not assigned to a genus 3.6%other genera 39.8%

Genera, mean relative abundance over 170 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).

Field coverage
fieldsamplescoverageR1R2R3R4
age_category175 100%
country175 100%175
health_condition175 100%175
subject_id175 100%175
antibiotic_exposure175 100%175
collection_date175 100%175
health_condition_detail175 100%175
timepoint_label175 100%175
Papers (1)
  • Fiber enrichment is not superior to dietary monitoring in MASLD: A dual-center, double-blind, placebo-controlled trial. 2025 PMID 41438070 PMC12721201 own_data
Details
Archive description

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease globally. Nutritional intake and Tthe gut-liver axis areis considered a key drivers in MASLD. Enriching diet of MASLD patients with fiber has been discussed a way to alter intestinal microbiota and thereby also disease. Oat beta glucan (β-Glucan) has shown potential in reducing blood cholesterol and protecting against steatohepatitis in preclinical models via its interaction with the gut microbiome. We aimed to compare the beneficial effect of nutritional monitoring and an enrichment of diet with different fibers e.g., soluble dietary supplementation with (oat branβ-Glucan) and insoluble fiber (spelt bran) compared with iso dietary fiber or to placebo (low in fiber) in patients with MASLD. Methods A diet for liver health (ADLH) was an investigator-initiated, randomisedrandomized, double-blind, placebo-controlled, multi-center dietary study conducted at the University Hospital RWTH Aachen, Department of Medicine III in Germany and Medical University of Vienna, University Hospital for Internal Medicine III, in Austria. Eligible participants were adults (aged 18-80 years) with steatotic liver disease (CAP >280dB) and without fibrosis or evidence of increased alcohol intake. After a three-week run-in-washout phase and an 1st assessment of dietary intake with a 3-day weighing protocol, participants were randomly allocated (1:1:1) through block randomization to receive oat bran( β-Glucan (4.5g, total dietary fiber: 11.7g) daily, spelt bran (=iso dietary fiber, total dietary fiber (11.7g) daily, or matched placebo (flakes mix, 2.1 g total dietary fiber) for 12 weeks. Randomization was done in blocks of 3. The primary endpoint was a decrease in CAP value and ALT-concentration in blood samples from baseline to end of treatment. Exploratory endpoints included fecal microbiota composition and function analyzed using shotgun metagenomics and serum bile acid profiling as well as markers of intestinal barrier function in serum. Trial registration: NCT03897218. Findings Between April, 2019, and October 2021, 48 patients with a history of MASLD and no significant alcohol consumption or other liver disease and fibrosis, were screened and randomly assigned to either oat bran β-Glucan, spelt bran iso dietary fiber or placebo. Interestingly, during the run-in when dietary intake was assessed by a 3d-weighing protocol pre-washout phase, participants demonstrated a significantly decreased in BMI, and ALT, AST and ɣ-GT levels being , which was associated with a significant increase in microbiota alpha diversity. The Ssustainability of these effects was most pronounced in patients receiving spelt bran or placebo, while patients in the oat bran group, However, these improvements were not sustained during the dietary intervention phase . Oat β-beta glucan did not improve steatosis or ALT levels thus failed to meet the primary endpoints. Relative reductions in AST at 12 weeks were significantly higher in participants in the iso dietary fiber compared to the oat-β-glucan group. While some correlations were observed between specific bacterial taxa, the overall microbiamicrobiota composition and l functions remained stable after the initial shift during the run-in phase, indicating that the and dietary groups, the overall impact of the dietary interventions did not cause any further changes. on microbiota composition and function was minimal. Serum bile acid levels remained unchanged across all groups . Conclusions Assessment of nutritional intake (3-day weighing dietary protocol) improved BMI, and markers of MASLD being related to changes in microbiota alpha diversity. Moreover, repeated assessment of nutritional intake in combination with the consumption of insoluble fiber or a placebo helped to maintain these improvements during the study and, in part throughout, the follow-up. dDuring the pre-washout phase significantly improved steatosis and AL …

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of adult by sonnet_x2 with confidence 0.72. Assay shotgun_dna.

  • host run.scientific_name · “human feces metagenome”
  • body site run.scientific_name · “human feces metagenome”
  • life stage study.description · “adults (aged 18-80 years)”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMEA115418327antibiotic_exposurenoR30.70paper.fulltext.methodsantibiotics treatment 6 weeks prior to the study
SAMEA115418327collection_date2021R10.90biosample.attribute:collection_date2021
SAMEA115418327countryATR10.90sample.attr.geographic_location_country_and_or_seaAustria
SAMEA115418327health_conditionliver_diseaseR40.50study.descriptionpatients with MASLD
SAMEA115418327health_condition_detailMetabolic dysfunction-associated steatotic liver disease (MASLD)R40.50study.descriptionpatients with MASLD
SAMEA115418327subject_idV002R10.85biosample.attribute:DESCRIPTIONWeek: 0W, Patient: V002
SAMEA115418327timepoint_labelweek 0R10.85biosample.attribute:DESCRIPTIONWeek: 0W, Patient: V002
Sequencing

175 runs over 175 samples · mean 12.15 Gbp per run (median 11.67 Gbp, total 2,126.87 Gbp; 175 runs with a base count) · layout PAIRED 175 · platform ILLUMINA 175 · models NextSeq 500 (175) · 97% of runs with a Sandpiper profile · first public 2025-08-16

Authors (15)

Brandt A first · Yergaliyev T · Halibasic E · Cyba A · Jaeger JW · Gong R · Hernández-Arriaga A · Schneider CV · Sjöland W · Molinaro A · Trauner M · Trautwein C · Camarinha-Silva A · Bergheim I · Schneider KM last

Downloads

PRJEB73985.csv.gz (5.2 KB) · parquet (76.2 KB) — all 175 samples, every field with route and confidence · PRJEB73985_determinations.csv.gz (8.3 KB) — 1,225 evidence rows

Samples (175 · every field this project has values for · hover a cell for its source)
Loading the sample table…